Tesamorelin, a synthetic hormone that stimulates growth hormone release, reduced visceral fat by 15% in human trials. The peptide was developed after doctors noticed HIV patients accumulating dangerous fat around their organs. A New England Journal of Medicine study found a 2 mg daily dose for six months outperformed placebo.
There is a peptide proven in multiple human randomized control trials to blast away visceral fat. Now, this is a huge deal if true, because visceral fat's that inflammatory fat that sits around your internal organs and contributes to cardiometabolic disease, even in lean, healthy people. It's kind of a sneaky fat. But the story of this peptide started somewhere weird. Doctors were noticing patients with HIV were accumulating visceral fat. Now, it's not because of the infection, but because the medications these patients are given. So Doctors wanted to find a way to offset the negative effects, to selectively reduce visceral fat, and they found Tesamorelin. Tesamorelin mimics your body's natural growth hormone-releasing hormone, which causes the release of your own growth hormone from the pituitary gland. Now, growth hormone can blast visceral fat, so Tesamorelin does too through this axis. Again, in multiple human randomized controlled trials, including in top medical journals like the New England Journal of Medicine, Tesamorelin was shown to reduce visceral fat. In this study, Tesamorelin at 2 milligrams for 6 months reduced visceral fat by 15% as compared to an increase in visceral fat in the placebo. But this is just the beginning of the nuance. If you want details, check the comments below. And if you want more optimistic science about the future of human bio-optimization and metabolic health, please subscribe.
